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have numerous side effects and to cause various old 
age disabilities.[1,2] Regarding the increase in ischemic 
heart diseases (IHDs) in the world, it has been estimated 
that this type of disease will be the main cause of death 
worldwide by the year 2020.[3] 
INTRODUCTION
Cardiovascular diseases are viewed worldwide as one 
of the main causes of death. They are also known to 
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Cardiovascular diseases had been assessed to be the cause 
of 28% of 50.4 million deaths and 9.7% of 1.4 billion years 
of life lost (YLLs) due to inabilities across the world in 
the year 1990. It has been estimated that by the year 2030 
when the population of the world will increase to 8.2 billion 
people, 30.5% of the world death toll will be caused by 
cardiovascular diseases.[4]
Half the death toll and 80% of the global burden of 
cardiovascular diseases are known to be from low-and 
medium-income countries and the number is increasing. 
Moreover, the highest number of deaths caused by 
cardiovascular diseases occur in the Eastern Mediterranean 
countries including Iran and these chronic diseases are 
turning increasingly epidemic.[5,6]
In the study of the global burden of disease (GBD) 2010, it 
has been mentioned that the burden of IHDs have increased 
by 29% from the year 1990 to 2010 and that over 90% of the 
disability-adjusted life years (DALYs) of ischemic cardio 
muscle diseases lead to the death of patients.[7] 
In the study of the burden of disease in Iran 2003, the DALYs 
of the ischemic cardio muscle disease (thoracic angina, 
stroke, heart failure) was ranked first with 437,709 years for 
women and fifth with 433,627 years for men. Unfortunately 
from the 871,336 DALYs in Iran, 60% still belongs to YLLs.[8] 
In a study conducted in 2010 in Iran, it was shown that from 
the burden of the disease under study, 860,000 years of life 
were lost in 2005 and by 2025, this number would increase 
to 1600,000 YLLs.[9]
Many of the 32 million people who experience heart attacks 
and strokes every year have one or more than one of the risk 
factors of this disease such as high blood pressure, diabetes, 
smoking, unhealthy diets, dyslipidemia, and sedentary 
lifestyle, all of which can be easily prevented or controlled. 
Studies have documented that elevated low-density 
lipoprotein (LDL)-cholesterol plays the most crucial role in 
atherosclerosis and IHDs. It is estimated that high cholesterol 
level is the cause of 18% of brain vascular diseases, 56% of 
ischemic cardiovascular diseases, and as a whole 7.9% of 
deaths across the world.[10] The mentioned factors are related 
to the lifestyle of the people, the economic, social, and cultural 
changes, which occur due to globalization, industrialization, 
and the aging of the population as well as stress and being 
from a low income status, which are also known to be the 
cause of such factors.[11]
To be able to control global epidemic of noncommunicable 
diseases (NCDs), early prevention based on international 
planning needs to take place. The aim of such an act is 
preventing the spread of epidemic diseases and somehow 
controlling them.[9] Health centers have been established 
from the year 2005 to 2009 by the management center of 
NCDs of the Ministry of Health to correct and adjust the 
lifestyle of the population to prevent and control such 
diseases.[1]
Although the awareness of the people has increased 
regarding the importance of controlling and preventing 
cardiovascular diseases, the number of people who refer 
to treatment centers due to such diseases is increasing 
by the day. Some of these people lose their lives because 
of the disease and others have to take medications for 
long periods of time.[12] Even on considering that the 
risk factors of cardiovascular diseases will not increase, 
in the next 30 years, a large number of people aged 
35-64 years will die due to this type of disease and the 
consequences of IHD will also increase in middle-aged 
people.[4]
For better planning regarding such a matter, officials need 
to pay closer attention to IHDs. Therefore, calculating the 
burden of IHDs can play a crucial role as data for better 
and more effective policy-making, designing and managing 
of intervening models. The current study therefore, aims 
to report the burden of IHDs in Iran by using data of the 
GBD study, 1990-2010. Furthermore, this study aims to 
compare the results with the similar findings and discuss 
the limitations of the GBD project.
MATERIALS AND METHODS
Using data of the GBD study 2010, this paper presents 
the trends in deaths and DALYs attributed to IHDs in 
Iran by sex and age from 1990 to 2010. The GBD study 
2010 was a comprehensive and systematic effort in data-
gathering and estimations of 291 types of diseases and 
injuries and 67 risk factors in 187 countries to calculate 
the global and regional comparative risk assessment of 
deaths and DALYs caused by different risk factors and 
diseases.[4,13-18]
The burden of disease, injuries, and risk factors are expressed 
in DALYs, which is mostly considered as a summary 
measurement of the population health gap.[13,16] DALYs 
show the sum of the YLL due to premature mortality in the 
population and the years lived with disability (YLDs).[4,13,16] 
YLLs as the first component of DALYs was calculated based 
on cause-of-death estimates for different causes of death, 
different age groups, and both sexes. Such estimates were 
developed with a broad and complete database of vital 
registration, verbal autopsy, and surveillance. To develop 
ensembles of the best performance models, the Cause of 
Death Ensemble model (CODEm) strategy was used,[18] 
in which uncertainty was taken with standard simulation 
methods.[19] 
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YLDs constituted the second component of DALYs, 
estimated by multiplying prevalence, the disability weight 
for a sequel, and the duration of symptoms. 
First, the estimation of prevalence for all age-sex-
country-year groups, followed through comprehensive 
systematic review of published and unpublished data, 
was performed on the prevalence, incidence, remission, 
and excess mortality and with a Bayesian meta-regression 
method of the GBD 2010.[18] Data collected through 
population-based surveys in five countries and an open 
Internet survey were used for generating disability 
weights. The details on the methods for analyzing the 
results of pairwise comparisons to produce disability 
weights are provided elsewhere.[4] Uncertainty in the 
disability weight for each sequel was disseminated into 
the estimations of YLDs (4).
The models used for estimating YLLs and YLDs generated 
the 95% uncertainty interval (95% UI) around each quantity 
of interest. Uncertainty from all inputs into the calculations 
of DALYs was propagated by means of Monte Carlo 
techniques.[18]
RESULTS
The age-standardized IHDs DALY specified rate 
decreased 31.25% over 20 years from 1990 to 2010 (from 
4729; 95% UI: 4,341-5,099 person-years per 100,000 to 
3,245; 95% UI: 2810-3529 person-years per 100,000). The 
decrease were 38.14% among women and 26.87% among 
men [Table 1].
The age-standardized IHDs death specefied rate 
decreased by 21.17% from 1990 to 2010 (222; 95% UI: 207-
243 person-years per 100,000 in 1990 to 175; 95% UI: 152-
190 person-years per 100,000 in 2010) amomg both sexes 
although IHDs death-specified rate increased 26.04% 
over these years (from 96; 95% UI: 88-104 person-years 
per 100,000 in 1990 to 121; 95% UI: 105-131person-years 
per 100,000 in 2010). This decreent in age-standardized 
death specified rate was 17.4% among men (from 264; 
95% UI: 242-302 person-years per 100,000 to 218; 95% 
UI: 179-242 person-years per 100,000) and was 26.96% 
among women (from 178; 95% UI: 161-199 person-years 
per 100,000 to 130; 95% UI: 107-146 person-years per 
100,000) [Table 2].
Although the crude YLL due to premature mortality 
increased by 11.21% from 1990 to 2010, the age-
standardized YLL rate decreased by 32.05% from 4580; 
95% UI: 4,180-4,970 person-years per 100,000 to 3,112; 
95% UI: 2,667-3,388 person-years per 100,000 over these 
years. Ta
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In men, this decrease from 1990 to 2010 was equal to 27.55% 
(from 5658; 95% UI: 5,116-6,442 person-years per 100,000 to 
4,099; 95% UI: 3294-4,555 person-years per 100,000), whereas 
in women this rate decreased by 39.26% over this period 
of time (from 3456; 95% UI: 3,014-3,885 person-years per 
100,000 to 2,099; confidence interval (CI) 95% 1,772-2,354 
person-years per 100,000) [Table 3].
The number of the YLDs increased from 39,399; 95% 
UI: 24,232-61,844 (91.11 growth) from 1990 to 2010. The 
crude YLD rate also grew 41.66% (from 72; 95% UI: 
44-113 person-years per 100,000 to 102; 95% UI: 60-157 
person-years per 100,000) during this period of time. 
However, the age-standaridized YLD rate decreased by 
4.28% from 1990 to 2010 (from 140; CI 95% 86-219 person-
years per 100,000 to 134; CI 95% 78-205 person-years per 
100,000). This decline in the age-standardized YLD rate 
among men and women were equal to 1.93% (from 155; 
95% UI: 92-248 person-years per 100,000 to 152; 95% UI: 
88-237 person-years per 100,000) and 7.25% (from 124; 
95% UI: 74-193 person-years per 100,000 to 115; 95% UI: 
69-178 person-years per 100,000) over the mentioned 
period of time, respectively [Table 4]. The percentage 
of total DALY, death, YLLs, and YLDs attributed to 
IHDs are presented in Table 5. The percentage of total 
DALYs, deaths, and YLLs increased significantly in 2010 
compared to 1990.
DISCUSSION
Based on our finding, in Iran the global burden of IHD 
in 2010 has reduced age-standardized IHD burden since 
1990. All age populations have decreased both YLLs 
and the burden of IHD. However, the crude YLD has 
increased in all age populations except for the middle 
age, i.e., between 50 years and 69 years. These results 
are not consistent with finding in the GBD 2010 study at 
the global level.[20] 
Moreover, the Prospective Urban Rural Epidemiologic 
(PURE) study found that among cardiovascular disease 
patients, YLD increased about 0.4%.[21] Our findings in 
which YLD decreased about 4.3% from 1990 to 2010 are not 
consistent with this study.
Since 1990, number of years of disability IHD has grown 
faster than the IHD mortality that is consistent with the 
study of the global burden of ischemic heart disease[7] 
while our findings on the decreased relative difference in 
YLD compared with mortality and YLL from 1990 to 2010 
are not consistent with that study, and it might suggest the 
need for a strategy shift in IHD treatment.[7] 
Anthony and Kim in their study conducted in 2004 
based on the data for all 192 member countries of the 
World Health Organization and revealed that the global 
variation in IHD mortality rates ranged 13 per 100,000 
in Kiribati to 456 per 100,000 in Turkmenistan, and the 
disease burden from ischemic heart disease ranged 145 
DALYs lost per 100,000 in Kiribati to 4,259 DALYs lost per 
100,000 in Afghanistan.[22] According to our findings, the 
age-standardized mortality rate and DALY were 175 and 
3,245 per 100 000, respectively, in 2010 and the relative 
difference reduction of about 21% and 31%, respectively, 
Table 2: Death rate and number of ischemic heart diseases in Iran by age and sex in 1990 and 2010
All causes and 
both genders
Number of deaths (thousands) [95% UI] Rates of death (per 100 000) [95% UI]
Ages 1990 2010 %Δ1 1990 2010 %Δ1
Both sexes
15-49 years 7,356 [6,221, 8,390] 8,068 [6,418, 9,687] 9.67 31 [26, 35] 18 [14, 21] –41.93
50-69 years 22,274 [19,921, 25,450] 25,621 [20,833, 29,069] 15.026 445 [398, 508] 295 [240, 335] –33.7
70+ years 19,822 [18,216, 21,808] 55,141 [48,100, 60,736] –72.182 2,104 [1,933, 2,315] 2,089 [1,822, 2,301] –0.71
All ages 52,874 [48,270, 57,076] 89,250 [77,673, 97,058] 68.79 96 [88, 104] 121 [105, 131] 26.04
Age-standardized — — — 222 [207, 243] 175 [152, 190] –21.17
Male
15-49 years 4,748 [3,879, 5,648] 5,823 [4,181, 7,331] 22.64 40 [33, 48] 25 [18, 32] –37.5
50-69 years 14,876 [12,949, 17,708] 17,701 [13,635, 20,626] 18.99 575 [501, 685] 409 [315, 476] –28.86
70+ years 11,321 [10,047, 12,998] 34,010 [28,738, 38,771] 200.415 2,350 [2,086, 2,698] 2,433 [2,056, 2,774] 3.53
All ages 32,865 [29,829, 36,979] 57,773 [47,413, 64,549] 75.78 119 [108, 134] 154 [126, 172] 29.41
Age-standardized — — — 264 [242, 302] 218 [179, 242] –17.4
Female
15-49 years 2,608 [1,879, 3,128] 2,245 [1,644, 2,945] –13.91 22 [16, 26] 10 [7, 13] –54.54
50-69 years 7,398 [6,239, 8,642] 7,920 [6,094, 9,499] 7.05 305 [257, 357] 182 [140, 218] –40.32
70+ years 8,502 [7,467, 9,770] 21,131 [17,363, 24,208] 148.54 18,46 [1,622, 2,122] 1,701 [1,398, 1,949] –7.85
All ages 20,009 [17,713, 22,315] 31,478 [26,116, 35,283] 57.31 74 [65, 82] 86 [72, 97] 16.21
Age-standardized — — — 178 [161, 199] 130 [107, 146] –26.96
1Between 1990 and 2010; UI = Uncertainty interval
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from 1990 to 2010. These estimates are included between 
the lower and upper bounds of mortality and DALY rates 
of Kim and Johnston’s report but these are more close to 
the upper bound. The results suggest the necessity for 
more intensive intervention to prevent and control the 
problem.
Our finding revealed that the age-standardized (5 years 
to 70+ years) mortality, YLL, YLD, and DALY rates were 
higher in men than in women. These findings were 
concordant with the study of age-standardized rates 
for 35-64-year-olds in the incidence of acute myocardial 
infarction from the MONICA study in 1985 to 1987 
and a Japanese study in 1989 to 1993. The incidence 
rates of Japan, China, the United Kingdom, Canada, 
Iceland the United States, the Czech Republic, New 
Zealand, Australia, Belgium, Germany, Switzerland, 
France, Spain, and Italy were higher in men than in 
women.[23,24]
It is important to consider that GBD report presents data 
at the national level and as we know in vast countries 
such as Iran; large variations exist in the prevalence and 
burden of IHDs at the regional and provincial levels. 
Therefore, providing an estimate of aggregated data on 
IHDs for all provinces of the country cannot be enough 
for policymakers to prioritize health problems at the 
provincial level. Moreover, the GBD is designed at the 
global level and these data are more accurate at the 
global level and at most at the national level. Because of 
using only national surveys, GBD estimations are more 
model-driven than data-driven. Therefore, subnational 
studies with more data on provincial and even county 
data to estimate the IHDs burden more accurately for 
providing evidence for health policy makers could be 
helpful. Recently, National and Sub-national Burden of 
Disease (NASBOD) study has been conducted in Iran 
to calculate the burden of diseases, injuries, and risk 
factors at the national and subnational levels from 1990 
to 2013.[25] 
It is also important to note that disease burden DALY is a 
measure of health loss alone, not financial or productivity 
loss due to disease such as hospitalization costs or 
medications of disease, lost work time, and involved family 
related to the burden of IHD.[13]
Exploring and describing the burden of IHD attributed to 
sex could potentially provide useful information on the 
importance of the problem. For instance, the percentage of 
age-standardized mortality and YLL rates are decreasing 
less in men compared to women from 1990 to 2010; this 
might provide some gender-specific actions for the public 
health system. Ta
bl
e 
3:
 Y
LL
 r
at
e 
an
d 
nu
m
be
r 
of
 is
ch
em
ic
 h
ea
rt
 d
is
ea
se
s 
in
 Ir
an
 b
y 
ag
e 
an
d 
se
x 
in
 1
99
0 
an
d 
20
10
A
ll 
ca
us
e 
an
d 
bo
th
 g
en
de
r
N
um
be
r 
of
 Y
LL
s 
(t
ho
us
an
ds
) [
95
%
 U
I]
R
at
es
 o
f Y
LL
 (p
er
 1
00
,0
00
) [
95
%
 U
I]
A
ge
s
19
90
20
10
%
Δ
1
19
90
20
10
%
Δ
1
Bo
th
 s
ex
es
15
-4
9 
ye
ar
s
37
4,
83
2 
[3
13
,4
07
, 
42
5,
49
6]
37
0,
54
5 
[2
99
,3
86
, 
44
0,
84
9]
−1
.1
4
1,
52
2 
[1
,2
60
, 
1,
73
5]
81
1 
[6
55
, 
96
5]
−4
6.
71
50
-6
9 
ye
ar
s
60
2,
70
0 
[5
39
,9
48
, 
68
5,
49
8]
68
8,
12
4 
[5
54
,6
53
, 
78
5,
95
4]
14
.17
11
,6
21
 [
10
,4
43
, 
13
,2
57
]
7,
92
7 
[6
,3
90
, 
9,
05
4]
−3
1.
78
70
+ 
ye
ar
s
25
1,
47
3 
[2
28
,2
72
, 
28
0,
14
8]
59
1,
94
1 
[5
11
,3
17
, 
65
3,
62
2]
13
5.
38
25
,9
72
 [
23
,5
42
, 
28
,9
04
]
22
,4
22
 [
19
,3
68
, 
24
,7
58
]
−1
5.
37
Al
l 
ag
es
1,
51
5,
59
0 
[1
,3
19
,2
00
, 
1,
69
9,
02
0]
1,
68
5,
54
0 
[1
,4
44
,2
50
, 
1,
83
8,
40
0]
11
.2
1
2,
69
3 
[2
,3
29
, 
3,
03
0]
2,
27
9 
[1
,9
53
, 
2,
48
6]
−1
5.
37
Ag
e-
st
an
da
rd
iz
ed
—
—
4,
58
0 
[4
,1
80
, 
4,
97
0]
31
12
 [
26
67
,3
38
8]
−3
2.
05
M
al
e
15
-4
9 
ye
ar
s
23
2,
58
4 
[1
87
,5
19
, 
27
8,
07
9]
26
5,
90
0 
[1
95
,2
01
, 
33
2,
23
6]
14
.3
2
1,
97
4 
[1
,5
92
, 
2,
36
1]
1,
15
0 
[8
44
, 
1,
43
7]
−4
1.
74
50
-6
9 
ye
ar
s
38
9,
58
8 
[3
38
,0
19
, 
46
6,
87
0]
47
89
60
 [
36
0,
07
0,
 5
64
,0
00
]
22
.9
4
15
,0
70
 [
13
,0
75
, 
18
,0
59
]
11
,0
58
 [
8,
31
3,
 1
3,
02
1]
−2
6.
62
70
+ 
ye
ar
s
14
3,
90
3 
[1
26
,7
50
, 
16
5,
83
4]
37
3,
35
5 
[3
15
,8
04
, 
42
7,
03
0]
15
9.
44
29
,8
75
 [
26
,3
14
, 
34
,4
28
]
26
,7
11
 [
22
,5
94
, 
30
,5
51
]
−1
0.
59
Al
l 
ag
es
92
6,
84
8 
[7
81
,5
42
, 
1,
08
4,
68
0]
1,
13
8,
05
0 
[8
97
,13
8,
 1
,2
70
,19
0]
22
.7
8
3,
34
9 
[2
,8
24
, 
3,
92
0]
3,
03
2 
[2
,3
90
, 
3,
38
4]
−9
.4
6
Ag
e-
st
an
da
rd
iz
ed
—
—
—
5,
65
8 
[5
,1
16
, 
6,
44
2]
4,
09
9 
[3
29
4,
45
55
]
−2
7.
55
Fe
m
al
e
15
-4
9 
ye
ar
s
13
0,
41
1 
[9
2,
78
7,
 1
56
,7
31
]
10
4,
64
4 
[7
8,
57
7,
 1
36
,2
20
]
-1
9.
75
1,
08
1 
[7
69
, 
1,
29
9]
46
4 
[3
48
, 
60
4]
−5
7.
07
50
-6
9 
ye
ar
s
19
2,
48
2 
[1
62
,2
71
, 
22
4,
02
8]
20
9,
16
3 
[1
63
,6
64
, 
24
9,
11
7]
8.
66
7,
94
2 
[6
,6
96
, 
9,
24
4]
4,
80
9 
[3
,7
63
, 
5,
72
8]
−3
9.
44
70
+ 
ye
ar
s
10
0,
79
4 
[8
7,
40
9,
 1
16
,17
5]
21
8,
58
6 
[1
78
,17
7,
 2
51
,7
97
]
11
6.
86
21
,8
88
 [
18
,9
82
, 
25
,2
29
]
17
,5
96
 [
14
,3
43
, 
20
,2
69
]
−1
9.
60
Al
l 
A
ge
s
54
9,
34
5 
[4
25
,4
43
, 
65
,3
17
6]
54
7,
48
6 
[4
65
,3
73
, 
61
4,
51
2]
-0
.3
3
2,
02
4 
[1
,5
67
, 
2,
40
6]
1,
50
3 
[1
,2
78
, 
1,
68
7]
−2
5.
74
Ag
e-
st
an
da
rd
iz
ed
—
—
—
3,
45
6 
[3
,0
14
, 3
,8
85
]
2,
09
9 
[1
,7
72
, 2
,3
54
]
−3
9.
26
1 B
et
w
ee
n 
19
90
 a
nd
 2
01
0;
 Y
LL
 =
 Y
ea
rs
 o
f l
ife
 lo
st
; U
I =
 U
nc
er
ta
in
ty
 in
te
rv
al
Maracy, et al.: Burden of ischemic heart diseases in Iran
Journal of Research in Medical Sciences| November 2015 | 1082
AUTHOR’S CONTRIBUTION
MRM contributed in the conception of the work, revising the 
draft, approval of the final version of the manuscript, and 
agreed for all aspects of the work. MTI contributed in the 
conception of the work, revising the draft, approval of the 
final version of the manuscript, and agreed for all aspects 
of the work. RK contributed in the conception and design 
of the work, drafting and revising the draft, approval of the 
final version of the manuscript, and agreed for all aspects of 
the work. AG drafting and revising the draft, approval of the 
final version of the manuscript, and agreed for all aspects 
of the work. FS drafting and revising the draft, approval 
of the final version of the manuscript, and agreed for all 
aspects of the work. RS contributed in the conception and 
design of the work, drafting and revising the draft, approval 
of the final version of the manuscript, and agreed for 
all aspects of the work. SD contributed in acquisition of 
date, revising the draft, approving the final version of the 
manuscript, and agreeing with all aspects of the work. SM 
drafting and revising the draft, approval of the final version 
of the manuscript, and agreed for all aspects of the work. 
HA contributed in acquisition of date, revising the draft, 
approving the final version of the manuscript, and agreeing 
with all aspects of the work. HA drafting and revising the 
draft, approval of the final version of the manuscript, and 
agreed for all aspects of the work. MQ contributed in the 
conception and design of the work, drafting and revising 
the draft, approval of the final version of the manuscript, 
and agreed for all aspects of the work.
Table 4: YLD rate and number of ischemic heart diseases in Iran by age and sex in 1990 and 2010
All cause and both 
gender
Number of YLDs (thousands) [95% UI] Rates of YLD (per 100,000) [95% UI]
Ages 1990 2010 %Δ1 1990 2010 %Δ1[]
Both sexes
15-49 years 11,837 [7,086, 18,674] 23,962 [13,799, 37,794] 102.43 50 [30, 78] 52 [30, 83] 4.0
50-69 years 20,630 [12,713, 32,496] 32,018 [18,635, 48,889] 55.20 412 [254, 649] 369 [215, 563] -10.43
70+ years 6,776 [4,176, 10,416] 19,164 [11,377, 28,906] 182.82 719 [443, 1,106] 726 [431, 1,095] 0.97
All ages 39,399 [24,232, 61,844] 75,297 [44,020, 115,996] 91.11 72 [44, 113] 102 [60, 157] 41.66
Age-standardized — — — 140 [86, 219] 134 [78, 205] -4.28
Male
15-49 years 6,547 [3,724, 10,696] 13,907 [7,838, 22,510] 112.41 56 [32, 91] 60 [34, 97] 7.142
50-69 years 11,863 [6,828, 19,006] 18,131 [10,176, 28,386] 52.83 459 [264,  735] 419 [235, 655] -8.71
70+ years 3,837 [2,257, 6,132] 11,371 [6,672, 17,597] 196.35 797 [469, 1,273] 814 [477, 1,259] 2.13
All ages 22,339 [13,166, 35,563] 43,503 [24,941, 68,414] 81 [48, 129] 116 [66, 182] 43.20
Age-standardized — — — 155 [92, 248] 152 [88, 237] -1.93
Female
15-49 years 5,289 [3,141, 8,446] 10,056 [5,720, 15,977] 44 [26, 70] 45 [25, 71] 2.27
50-69 years 8,767 [5,147,  13,734] 13,887 [8,048, 21,892] 362 [212, 567] 319 [185, 503] -11.87
70+ years 2,939 [1,740, 4,554] 7,793 [4,717, 11,983] 638 [378, 989] 627 [380, 965] -1.72
All ages 17,061 [10,186, 26,746] 31,794 [18,920, 49,377] 63 [38, 99] 87 [52, 136] 38.09
Age-standardized — — — 124 [74, 193] 115 [69, 178] -7.25
1Between 1990 and 2010; YLDs = Years lived with disability; UI = Uncertainty interval
Table 5: Percentage of total DALYs, deaths, YLLs, 
and YLDs attributed to ischemic heart diseases in Iran 
in 1990 and 2010
All ages, all causes, 
and both sexes
1990 2010
DALYs [95% UI] 6.89 [5.98, 8.00] 9.09 [7.64, 10.34]
Deaths [95% UI] 16.46 [14.50, 18.25] 25.43 [21.27, 28.31]
YLLs [95% UI] 9.26 [7.89, 10.59] 16.03 [12.99, 18.16]
YLD [95% UI] 0.68 [0.43, 1.01] 0.85 [0.52, 1.23]
DALYs = Disability-adjusted life years; YLLs = Years of life lost; YLDs = Years lived with 
disability; UI = Uncertainty interval
CONCLUSION
Despite decreasing age-standardized IHD of mortality, 
YLL, YLD, and DALY rates from 1990 to 2010 in Iran, the 
population growth and aging increased the global burden 
of IHD. In Iran, YLL has decreased more than IHD deaths 
and YLD since 1990 but IHD mortality remains the greatest 
contributor to disease burden. 
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